Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $568.53M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.88M
Average 2.56M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Abivax S.A. NASDAQ:ABVX | $7.67B | $87.58 | Not rated | -18.1 | -27.87% |
Immunovant, Inc. NASDAQ:IMVT | $7.07B | $34.18 | Not rated | -14.3 | +40.19% |
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +115.36% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -24.49% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | $8.16 | Not rated | -3.1 | -20.27% |
Q32 Bio Inc. NASDAQ:QTTB | $260.64M | $8.71 | Not rated | 5.4 | +278.51% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | $2.13 | Not rated | -2.9 | -30.82% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -9.45% |
Continue the stock analysis
Jump to another research area for this company.